Cybin Inc. (CYBN) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Toronto, ON, 加拿大. 现任CEO为 Eric So.
CYBN 拥有 IPO日期为 2019-09-13, 50 名全职员工, 在 NYSE, 市值为 $413.02M.
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
